Curaleaf International, in collaboration with Jupiter Research, a subsidiary of TILT Holdings, said it has secured regulatory approval for the first handheld liquid inhalation device designed for precise medical cannabis administration.
The liquid inhalation device is now certified as a Class IIa medical device, meeting European regulatory standards. The device includes a magnetic snap-in cartridge and a rechargeable power supply.
EU certification supports deployment in multiple global markets and once commercialized, will enable healthcare professionals to recommend the device offered by Curaleaf International in countries including European countries, the UK, Canada, and regions across Australasia.
"Achieving EU medical certification is more than a regulatory milestone—it's a signal that medical cannabis innovation is moving into the mainstream of global healthcare. We're proud to offer a device that meets the highest standards of safety and quality, and we look forward to supporting patients and healthcare providers across Europe and beyond with a new, accurate and discrete option for treatment," said Curaleaf CEO Boris Jordan.
